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Abstract
Acute myeloid leukemia with inv(3)(q21;q26.2)/t(3;3)(q21;q26.2) (3q26 AML) is a rare disease with poor prognosis and
median survival of <1 year. To evaluate allogeneic stem cell transplantation (alloHSCT) in the treatment of 3q26 AML, we
studied 98 patients reported to the European Society for Blood and Marrow Transplantation between 1995 and 2013.
Majority of patients were transplanted using peripheral blood, from unrelated donors and after myeloablative conditioning.
Fifty-three patients were transplanted with active disease and 45 in complete remission. After a median follow-up of
47 months, 2 year leukemia-free survival (LFS), overall survival (OS), relapse incidence (RI), non-relapse mortality (NRM),
and graft-versus-host disease-free, relapse-free survival (GRFS) probabilities were 20%, 26%, 64%, 16%, and 14%,
respectively. Two-year LFS and OS probabilities for patients transplanted in CR vs. those transplanted in active disease were
23.8 vs. 17% (p=NS) and 34.9 vs. 18.9% (p=NS), respectively. In multivariate analysis CR was the only factor associated
with a trend for better LFS (p= 0.05, HR 0.64) and OS (p= 0.06, HR 0.65). CR also significantly influenced GRFS (p=
0.01; HR 0.55) and NRM (p= 0.02; HR 0.27). The results suggest that a proportion of patients might benefit from the
procedure, especially if performed in CR.
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The outcome in AML strongly depends on cytogenetic and
molecular abnormalities. In 2008 and recently revised
Classification of Tumors of Haematopoietic and Lymphoid
Tissues AML with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2);
RPN1-EVI1 (3q26 AML) is listed as a separate entity [1].
Recent findings led to proposed renaming this type of leu-
kemia as AML with inv(3)(q21;q26.2)/t(3;3)(q21;q26.2);
GATA2; MECOM [2]. Patients may present initially with
AML de novo or secondary, arising from myelodysplastic
syndrome (MDS). Additional cytogenetic abnormalities are
frequent with chromosome 7 monosomy being the most
common, followed by complex karyotype. Patients with
3q26 AML usually have higher hemoglobin concentration,
leukocyte, and platelet counts compared to their normal
karyotype AML counterparts [3]. Multilineage dysplasia is
frequent with a typical megakaryocytes as the most pro-
minent feature [1]. The immunophenotypic profile of leu-
kemic cells is not specific but high co-expression of
myeloid markers (CD33, CD13, and CD117) with uncom-
mitted markers (CD34, HLA-DR) is most commonly
detected, which suggests evolution from early progenitor
[4]. European Leukemia-Net recommendations classify
3q26 AML as high-risk disease [5]. In a large series of
younger patients within United Kingdom Medical Research
Council trials, 3q26 AML had the lowest chance of
achieving CR among defined cytogenetic groups with 5-
year survival probability of 5% and median survival of
10 months [6, 7]. 3q26 AML remains a very rare disease
with frequency of about 1% of all AMLs [8]. In such
instances retrospective analyses, with all their shortcomings
considered, are the only way to evaluate therapeutic inter-
ventions. Several studies indicate benefit of allogeneic
hematopoietic stem cell transplantation (alloHSCT) even in
patients with high risk or refractory AML [9, 10]. Lack of
efficient conventional therapy prompted Acute Leukemia
Working Party (ALWP) of the European Society for Blood
and Marrow Transplantation (EBMT) to analyze alloHSCT
outcome in 3q26 AML patients.
Subjects and methods
The analysis includes all adult 3q26 AML patients trans-
planted from matched related or unrelated donors between
1995 and 2013 reported to the EBMT database with ade-
quate accuracy, who met cytogenetic WHO definition cri-
teria. In cases of imprecise reporting of karyotype
information (e.g., t(3;3)) the centers were asked to provide
copies of cytogenetic reports from the time of diagnosis.
Thus, all cytogenetic data was centrally verified. The
patients could be transplanted with either bone marrow or
peripheral stem cells, after any conditioning and at any
stage of the disease. Complete remission before transplan-
tation was defined as ≤5% blasts in bone marrow smears.
Fifty EBMT centers participated in the study. The study was
based on Minimum Essential Data-A (MED-A) and follow-
up forms. Since 1990 all patients reported to the EBMT
provide informed consent authorizing the use of their data
for research purposes.
Statistical analyses and definitions
The endpoints of the study were 2-year leukemia-free sur-
vival (LFS), overall survival (OS), relapse incidence (RI),
non-relapse mortality (NRM), and graft-versus-host dis-
ease-free, relapse-free survival (GRFS). LFS was defined as
survival without disease recurrence. OS was defined as time
from transplantation to death of any cause. Relapse was
defined as morphologic evidence of disease recurrence in
the bone marrow cytology with >5% blast cells or presence
of chloroma. NRM was defined as death of other causes
than relapse or progression. GRFS was defined according to
Ruggeri et al.[11] as survival without symptoms of acute
GvHD grade III–IV, severe chronic GvHD and progression
of the disease [11]. Acute graft-versus-host disease was
graded according to Glucksberg criteria [12]. Variables
considered in statistical analysis were diagnosis (de novo or
MDS related AML), type of chromosome 3 involvement
(inv(3) or t(3;3)), patient age ≤ or >50 years, remission
status at transplantation, presence of additional chromosome
abnormalities (monosomy 7 and complex karyotype),
patient and donor CMV IgG serology (positive or negative),
type of donor (matched sibling donor or unrelated) and sex-
matching (female to male transplant). Transplant variables
included source of stem cells, intensity of conditioning and
in vivo T-cell depletion. Cumulative incidence functions
(CIF) were used to estimate RI and NRM in a competing
risks setting, because death and relapse compete with each
other. Chronic GvHD was studied as a time-dependent
variable with relapse and death being the competing events.
Probabilities of LFS, OS, and GRFS were calculated using
the Kaplan–Meier estimates. Univariate analyses were
performed using Gray’s test for CIF and the log-rank test for
LFS and OS. Associations of patient and graft character-
istics with outcomes were evaluated in multivariate analy-
sis, using Cox proportional hazards model. Variables
associated with p-value <0.15 by univariate analysis were
included in the final model. We also included factors known
as possibly influencing the outcome, such as age or donor
type. All tests were two-sided. The type-1 error rate was
fixed at 0.05 for determination of factors associated with
time to event outcomes. Statistical analyses were performed
with SPSS 22 (SPSS Inc./IBM, Armonk, NY) and R 3.2.3
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(R Development Core Team, Vienna, Austria) software
packages.
Results
The study group consisted of 98 patients transplanted
between 1995 and 2013. The median year of transplantation
was 2007. Table 1 presents essential characteristics of the
cohort. The median age of patients was 44 years (range
18–76; IQR 35–54) and more than half of them were male.
AlloHSCT was performed at median of 159 days from
primary diagnosis (range 46–770; IQR 115–204). In 65% of
patients inv(3) was identified, while 35% showed t(3;3)
mutation. EVI1 overexpression was confirmed only in 21
patients. The type of chromosome 3 abnormalities, the
presence of additional chromosomal aberrations and AML
evolving from MDS were seen with comparable frequencies
among patients transplanted in remission or active disease.
Chromosome 7 monosomy was the most frequent additional
mutation and was reported in 49% of the patients. In
addition complex karyotype was found in 22 out of 84
patients with available information. At transplantation 54%
of the patients had active disease: 38% of patients were
Table 1 AlloHSCT for 3q26 AML: patients’ and donors’
characteristics
N %




Type of chromosome 3
abnormality
t(3;3) 34 35
inv (3) 64 65







Complex karyotypeb No 62 74
Yes 22 26
Not available 14
Patient sex Male 54 55
Female 44 45
Donor sex Male 62 55
Female 36 45
Female to male transplant No 79 81
Yes 19 19
Donor type MSD 44 45
UD 54 55
Source of stem cells BM 18 18
PB 80 82
Disease status at transplant CR 1 43 44
CR 2 2 2
Active disease 53 54
Primary refractory 37 38
First relapse 16 16
Patient CMV serology Negative 33 36
Positive 60 64
Missing 5
Donor CMV serology Negative 49 53
Positive 43 47
Missing 6
















In vivo T-cell depletion No 58 60
Yes 39 40
Missing 1
Engraftment No 2 2
Yes 94 98
Missing 2
Acute GvHD 0–I 63 66
II–IV 33 34
Missing 2
Chronic GvHD No 75 77
Yes 22 23
Missing 1
AML acute myeloid leukemia, MDS myelodysplastic syndrome, MSD
matched sibling donor, UD unrelated donor, BM bone marrow, PB
peripheral blood, CB cord blood, CR complete remission, CMV
cytomegalovirus, MAC myeloablative conditioning, Bu busulfan, Cy
cyclophosphamide, TBI total body irradiation, RIC reduced intensity
conditioning, Flu fludarabine, Flamsa fludarabine-amsacrine-cytara-
bine, Mel melphalan, GvHD graft-versus-host disease, CsA cyclos-
porine A, Mtx methotrexate, MMF mycofenolate mofetil, Tacro
tacrolimus, Siro sirolimus
a Three patients reported as secondary AML due to previous
chemotherapy for a solid tumor and 9 transformed from MDS
b Karyotype with ≥3 abnormalities
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primary refractory and 16% were in first relapse. Myeloa-
blative conditioning (MAC) was used in 62% with cyclo-
phosphamide/total body irradiation being the most
frequently applied regimen. Reduced intensity conditioning
(RIC) incorporated different protocols based mostly on
fludarabine. Grafts from unrelated donors constituted 55%
of the transplants and peripheral blood was the main source
of stem cells. Graft-versus-host disease prophylaxis was
based on cyclosporine in almost all patients. T-cell deple-
tion in vivo with antitymocyte globulin was performed in 36
and with anti-CD52 antibodies in three patients transplanted
from unrelated donors. Engraftment was achieved in 98% of
patients with available data, at a median of 16 days (range
9–74). For two patients the data were missing and two
patient did not engraft. Grade II–IV aGvHD was reported
for 34% and cGvHD for 23% of patients. The median
follow-up for surviving patients was 47 months (range
14–172). Of 53 patients transplanted while not in remission,
35 (66%) achieved CR after alloHSCT. During the follow-
up 81 (83%) patients died. Disease relapse or progression
was the primary cause of death in 51 cases, followed by
infection in 18 and GvHD in 5 cases. The year of trans-
plantation (before or after 2007) did not influence the
endpoints, although a trend toward less NRM was seen in
patients transplanted after 2007 (11.7 vs. 22.2%, p= 0.08).
Fourteen of relapsing patients received donor lymphocyte
infusions (DLI) but only one patient was reported alive at
82 days post DLI. Twelve patients died due to original
disease and one due to infection. Additionally 12 patients
underwent second alloHSCT in an attempt to treat relapse.
Of those, only one patient was alive at 215 days, while
others died at a median time of 166 days (range 9–1375)
after second transplant due to AML (7), infection (3), or
hemorrhage (1).
Leukemia-free survival
Probability of 2-year LFS in the whole cohort was 20%
(95% CI, 11–24%). In univariate analysis no factors were
associated with improved LFS (Table 2). In multivariate
analysis a trend toward better LFS was seen for patients
transplanted in CR vs. those not in remission, with p= 0.05
and hazard ratio (HR) 0.64 (Table 3), (Fig. 1a). Patients
transplanted in CR had 24% probability of LFS at 2 years.
For those not in remission LFS probability was estimated at
17%. Other analysed variables such as cGvHD (HR= 1.09
(0.56–2.1); p= 0.8) or intensity of conditioning, were not
found to have impact on LFS.
Overall survival
Probability of 2-year OS was 26% (95% CI, 17–35%)
(Fig. 1b). None of the analyzed factors in univariate
analysis influenced OS (Table 2), although CR before
transplantation was associated with a trend for better OS in
multivariate analysis (p= 0.06; HR 0.65) (Table 3). For
patients transplanted in CR vs. those not in CR, 2-year
probability of OS was calculated at 35% vs. 19%,
respectively.
Relapse incidence
In patients who relapsed, the median time to disease
recurrence was 4 months (range 0.4–32). Two-year risk of
relapse was estimated at 64% (95% CI, 53–72%) (Fig. 1c).
In univariate analysis it was significantly higher for patients
with additional chromosome 7 monosomy (p= 0.04), but
this finding was not confirmed in multivariate analysis as an
independent risk factor (Tables 2 and 3). Chronic GvHD did
not influence the risk of relapse (HR= 0.65 (0.28–1.49);
p= 0.31). Multivariate analysis showed a trend toward
decreased risk of relapse for transplants from unrelated
donors (p= 0.09; HR= 0.63 (0.37–1.07)) (Table 3).
Non-relapse mortality
The risk of 2-year NRM was 16% (95% CI, 10–24%) and
was lower for patients transplanted in CR. Thus, a trend for
decreased NRM in patients transplanted in CR was noted in
univariate (9% vs. 23%; p= 0.03) and it was confirmed in
multivariate analysis (p= 0.02; HR 0.27). In addition,
chromosome 7 monosomy was found to be significantly
associated with decreased NRM risk (7.8 vs. 25.6%;
p= 0.02 in univariate and p= 0.05; HR 0.35 in multivariate
analyses) (Tables 2 and 3).
Graft-versus-host disease-free, relapse-free survival
Two-year probability of GRFS was 14% (95% CI, 7–21%)
(Fig. 1d). The only factor associated with higher probability
of GRFS in our study was transplantation in CR, 18 vs. 11%
at 2 years, which was confirmed in both univariate and
multivariate analyses (p= 0.02 and p= 0.01; HR 0.55,
respectively) (Tables 2 and 3).
Patients transplanted in remission
A separate analysis (data not shown) was performed for 45
patients transplanted in CR. In univariate analysis age >50
years was found to negatively affect LFS, OS, RI, and
GRFS (p-values 0.02; 0.03; 0.03, and 0.03 respectively). In
multivariate analysis the age retained its significance for
LFS (p= 0.048, HR 2.0) and RI (p= 0.035, HR 2.3).
Intensity of conditioning significantly influenced OS in
univariate analysis. Two-year OS probability with MAC
was estimated at 41.5% and RIC at 19% (p= 0.036);
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Table 2 AlloHSCT for 3q26 AML: univariate analysis of prognostic factors. Two-year estimates for each variable category are provided
Variables LFS (95% CI) OS (95% CI) RI (95% CI) NRM (95% CI) GRFS (95% CI)
Diagnosis De novo 17.4% (9.3–25.4) 23.1% (14.2–32) 64% (52.8–73.3) 18.6% (11.2–27.5) 11.6% (4.9–18.4)
Secondary 41.7% (13.8–69.6) 50% (21.7–78.3) 58.3% (24.7–81.2) 0% (0–0) 33.3% (6.7–60)
P-value 0.19503 0.11816 0.86615 0.32361 0.21069
Type of chromosomal inv (3) 16.7% (7.5–26) 24.7% (14–35.3) 64.4% (51–75) 18.9% (10.3–29.4) 12.2% (4–20.3)
Abnormality t(3;3) 26.5% (11.6–41.3) 28.9% (13.5–44.3) 61.8% (42.8–76) 11.8% (3.6–25.3) 17.6% (4.8–30.5)
P-value 0.24362 0.13734 0.91808 0.23957 0.43238
Age at transplant ≤50 19.9% (9.7–30) 24.7% (13.7–35.7) 60.1% (46.3–71.5) 20% (10.9–31.1) 13.3% (4.7–21.9)
>50 20.7% (7.7–33.7) 28.5% (14–43) 68.7% (50.7–81.3) 10.5% (3.3–22.8) 15.4% (3.7–27)
P-value 0.6529 0.58007 0.34052 0.6078 0.77677
Remission status Active disease 17% (6.9–27.1) 18.9% (8.3–29.4) 60.4% (45.6–72.3) 22.6% (12.3–34.8) 11.3% (2.8–19.9)
At transplant CR 23.8% (11.2–36.5) 34.9% (20.8–49) 67.3% (50.8–79.3) 8.9% (2.8–19.5) 17.5% (6.3–28.7)
P-value 0.11692 0.13045 0.77255 0.039317 0.019438
Monosomy 7 No 21.8% (10.3–33.3) 25.2% (12.9–37.4) 54% (39–66.8) 24.2% (13.2–36.9) 18% (7.4–28.6)
Yes 18.8% (7.7–29.8) 27.1% (14.5–39.7) 72.9% (57.5–83.5) 8.3% (2.6–18.5) 10.4% (1.8–19.1)
P-value 0.81291 0.91273 0.040942 0.039295 0.33367
Complex caryotype No 24.1% (13.4–34.8) 30.5% (19–42) 64.6% (51.1–75.3) 11.3% (4.9–20.6) 16.1% (7–25.3)
Yes 13.6% (0–28) 17% (0.8–33.3) 63.6% (38.7–80.6) 22.7% (7.6–42.6) 8.7% (0–20.2)
P-value 0.24058 0.29048 0.91835 0.30015 0.18218
EVI1 overexpression No 6.3% (0–14.6) 12.5% (1–24) 81.2% (61.5–91.5) 12.5% (3.5–27.6) 3.1% (0–9.2)
Yes 27.8% (8.3–47.3) 38.1% (17.3–58.9) 57.9% (32.8–76.5) 14.3% (3.4–32.8) 14.3% (0–29.3)
P-value 0.15133 0.12536 0.18071 0.8244 0.31941
Type of donor MSD 13.3% (3.1–23.4) 19.1% (7.1–31.2) 70.5% (54.1–81.9) 16.3% (6.9–29.2) 11.4% (2–20.7)
UD 25.9% (14.2–37.6) 31.5% (19.1–43.9) 57.4% (42.9–69.5) 16.7% (8.1–27.8) 16.7% (6.7–26.6)
P-value 0.29813 0.4735 0.21282 0.66097 0.96696
Female to male transplant No 20% (11.1–28.8) 26.1% (16.3–35.9) 62.3% (50.4–72.1) 17.8% (10.2–27.1) 13.8% (6.2–21.5)
Yes 21.1% (2.7–39.4) 26.3% (6.5–46.1) 68.4% (40.8–85.2) 10.5% (1.6–29.4) 15.8% (0–32.2)
P-value 0.99886 0.80753 0.43738 0.30529 0.95591
Source of stem cells BM 16.7% (0–33.9) 22.2% (3–41.4) 55.6% (28.7–75.8) 27.8% (9.4–49.9) 11.1% (0–25.6)
PB 20.9% (11.9–29.9) 27.2% (17.3–37) 65.3% (53.5–74.8) 13.8% (2.6–34.2) 14.8% (7–22.6)
P-value 0.92335 0.91784 0.29276 0.22806 0.82942
Patient CMV serology Negative 21.2% (7.3–35.2) 24.2% (9.6–38.9) 54.5% (35.7–70) 24.2% (11.1–40.1) 12.1% (1–23.3)
Positive 19.4% (9.2–29.6) 26.1% (14.8–37.3) 67.2% (53.3–77.8) 13.4% (6.2–23.5) 14.7% (5.6–23.7)
P-value 0.9929 0.61219 0.26056 0.11074 0.66832
Donor CMV serology Negative 22.4% (10.8–34.1) 28.6% (15.9–41.2) 59.2% (43.8–71.6) 18.4% (8.9–30.5) 12.2% (3.1–21.4)
Positive 17.9% (6.2–29.7) 25% (11.9–38.1) 65.8% (48.7–78.4) 16.3% (7–28.9) 16.3% (5.2–27.3)
P-value 0.45188 0.63476 0.44909 0.72426 0.83082
Conditioning regimen MAC 21.3% (11–31.6) 31.1% (19.5–42.8) 59% (45.4–70.3) 19.7% (10.7–30.6) 13.1% (4.6–21.6)
RIC 24% (10.1–37.9) 29.5% (14.7–44.3) 65.2% (46.9–78.5) 10.8% (3.3–23.5) 18.5% (5.9–31.2)
P-value 0.72716 0.61753 0.29764 0.63309 0.75004
In vivo T cell No 17.1% (7.3–26.8) 21.6% (10.8–32.4) 67.2% (53.3–77.9) 15.7% (7.6–26.5) 10.3% (2.5–18.2)
Depletion Yes 25.6% (11.9–39.3) 33.3% (18.5–48.1) 56.4% (39.1–70.5) 17.9% (7.8–31.5) 20.5% (7.8–33.2)
P-value 0.38146 0.40773 0.15999 0.40626 0.3542
LFS leukemia-free survival, OS overall survival, RI relapse incidence, NRM non-relapse mortality, GRFS graft-versus-host disease-free, relapse-
free survival, aGvHD acute graft-versus-host disease, cGvHD chronic graft-versus-host disease, CR complete remission, MSD matched sibling
donor, UD unrelated donor, BM bone marrow, PB peripheral blood, CMV cytomegalovirus, MAC myeloablative conditioning, RIC reduced
intensity conditioning
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however, the significance was not confirmed in multivariate
analysis (p= 0.2; HR 1.82). The best results were seen in
individuals aged <50 who received MAC (n= 19). In this
small subgroup of patients probabilities of 2-year LFS, OS,
RI, NRM, and GRFS were 42.1% (95% CI: 19.9–64.3),
46.3% (95% CI: 23.5–69.2), 47.4% (95% CI: 23.5–68),
10.5% (95% CI: 1.7–29) and 31.6% (95% CI: 10.7–52.5),
respectively (Table 4).
Discussion
AML with t(3;3)(q21;q26)/inv(3)(q21;q26) is a well char-
acterized entity with a very poor outcome, demonstrated by
the virtual absence of long-term survivors after
conventional AML-type chemotherapy. In an effort to
evaluate the added benefit of alloHSCT in patients diag-
nosed with acute myeloid leukemia with 3q26 AML we
performed this registry-based study. The analysis showed
limited capability of efficient long-term disease control with
alloHSCT, which was obtained only in approximately one
quarter of the patients. The failure was due mainly to a very
high rate of relapse or progression after transplant. None-
theless, alloHSCT arises currently as the only strategy that
provides durable response in a subset of 3q26 AML
patients. Remission status at transplantation was the only
factor with a moderately positive effect on transplant out-
come, probably identifying a subgroup of patients with a
more chemosensitive disease and lower tumor burden.
Other transplant-related variables, such as age, conditioning
intensity, T-cell depletion strategies or donor type, did not
influence outcome in the whole group. However in patients
transplanted in CR, age ≤50 years and MAC were bene-
ficial. On the other hand the limited population size of the
study and the fact that minority of patients were in CR at
transplantion preclude identification of the best transplan-
tation strategy in this setting. The first important finding of
our analysis was that only 46% of patients were in first or
second complete remission and, therefore, achieved an
optimal response status at time of transplant. This confirms
the difficulty in obtaining and maintaining remission in
3q26 AML patients with currently used standard che-
motherapy regimens [7]. Thus, the majority of the patients
had active disease and the transplantation was performed as
a salvage procedure. Nevertheless the findings of our study
confirm the possibility of obtaining long-term disease con-
trol with allogeneic transplantation in a subset of 3q26
AML patients, with a 2-year LFS and OS of 20% and 26%,
respectively. These outcome results are comparable to those
achieved in very high-risk AML populations, such as
patients with determined highly adverse genetic categories
like monosomal karyotype or TP53 mutated AML and
patients with primary refractory disease or refractory relapse
[13, 14]. In those studies, remission status at transplantation
was also a key prognostic factor, as confirmed in the present
study, being the only variable associated with better LFS
and OS. Therefore improvement of pre-transplant treatment
to obtain a deeper response on one hand and developing
better strategies to maintain response post-transplant on the
other, seem indispensable in order to increase probability of
long-term success after alloHSCT. Epigenetic modification
with azacitidine, although demonstrating positive results
with improved treatment outcome as compared to standard
chemotherapy in specific high-risk AML subsets, has a
limited role in 3q26 AML [15]. Recent research threw light
on the biology of 3q26 AML and revealed that the chro-
mosomal abnormalities that define the disease result in EVI1
(or MECOM) overexpression due to GATA2 enhancer
Table 3 AlloHSCT for 3q26 AML: multivariate analysis for all
patients
p-value HR 95% CI
Lower Upper
LFS Age >50y 0.36 1.24 0.79 1.95
inv(3) vs. t(3;3) 0.22 1.35 0.84 2.18
Monosomy 7 0.82 1.05 0.67 1.65
CR vs. active disease 0.05 0.64 0.41 1.00
UD vs. MSD 0.13 0.70 0.44 1.12
OS Age >50y 0.31 1.27 0.80 2.02
inv(3) vs. t(3;3) 0.11 1.47 0.92 2.37
Monosomy 7 0.87 1.04 0.66 1.63
CR vs. active disease 0.06 0.65 0.41 1.02
UD vs. MSD 0.24 0.76 0.48 1.21
RELAPSE Age >50y 0.31 1.30 0.78 2.17
inv(3) vs. t(3;3) 0.67 1.12 0.66 1.90
Monosomy 7 0.18 1.42 0.85 2.37
CR vs. active disease 0.36 0.79 0.47 1.31
UD vs. MSD 0.09 0.63 0.37 1.07
NRM Age >50y 0.87 1.09 0.40 2.98
inv(3) vs. t(3;3) 0.08 2.73 0.88 8.50
Monosomy 7 0.05 0.35 0.12 1.02
CR vs. active disease 0.02 0.27 0.09 0.85
UD vs. MSD 0.98 1.01 0.37 2.76
GRFS Age >50y 0.83 0.95 0.61 1.49
inv(3) vs. t(3;3) 0.43 1.21 0.76 1.92
Monosomy 7 0.35 1.23 0.79 1.91
CR vs. active disease 0.01 0.55 0.35 0.87
UD vs. MSD 0.90 1.04 0.61 1.76
In vivo TD 0.18 0.69 0.40 1.19
LFS leukemia-free survival, OS overall survival, RI relapse incidence,
NRM non-relapse mortality, GRFS graft-versus-host disease-free,
relapse-free survival, aGvHD acute graft-versus-host disease, cGvHD
chronic graft-versus-host disease, CR complete remission, MSD
matched sibling donor, UD unrelated donor, TD T-cell depletion
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reposition from 3q21 to EVI1 locus at 3q26.2 and in GATA2
haploinsufficiency at its original locus [16, 17]. Based on
those findings, early in vitro experiments give some hope
for controlling the disease in the future by silencing EVI1
overexpression, which can be obtained by disrupting
superenhancers like GATA2 or targeting the essential
interaction of PLDLS domain of EVI1 with C-terminal
DNA binding protein [16, 18]. The molecular analysis in
our group of patients was not possible as only in 21 cases
EVI1 overexpression was reported and in majority of
patients it was not evaluated. Paucity of molecular data is a
typical shortcoming of large databases and only prospective
clinical trials are able to overcome this obstacle. Potential
relevance of developing effective post-transplant interven-
tion for a sustained response is reflected in the observation
that 66% of patients allografted active disease achieved a
morphologic CR after alloHSCT; however, 2-year LFS and
OS was only 17% in this refractory patient population.
Targeting CD33 with conjugated antiCD33 antibody gem-
tuzumab ozogamycin (GO), highly expressed in 3q26
AML, might be an effective post-transplant intervention in
this entity. As recently reported, 14 pediatric patients with
CD33+ AML treated with low-dose GO post-transplant,
showed promising results with 1-year OS of 78% [19].
Several studies indicate a beneficial effect of chronic and
mild forms of acute GvHD on LFS and relapse incidence in
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Fig. 1 AlloHSCT for 3q26 AML: a leukemia-free survival; b overall survival; c cumulative incidence of relapse; d graft-versus-host-free, relapse-
free survival
Table 4 AlloHSCT for 3q26 AML: 2-year outcome probabilities for
patients aged <50 transplanted in complete remission with
myeloablative conditioning (n= 19)
LFS 42.1% (95% CI: 19.9–64.3)
OS 46.3% (95% CI: 23.5–69.2)
RI 47.4% (95% CI: 23.5–68)
NRM 10.5% (95% CI: 1.7–29)
GRFS 31.6% (95% CI: 10.7–52.5)
LFS leukemia-free survival, OS overall survival, RI relapse incidence,
NRM non-relapse mortality, GRFS graft-versus-host disease-free,
relapse-free survival
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not found to exert positive impact on LFS or RI. Of note,
the median time to relapse in our study was 4 months,
which is probably too short for graft-versus-leukemia (GvL)
effect to develop. In multivariate analysis, we observed a
trend for lower relapse risk in patients receiving grafts from
unrelated donors, indicating possible stronger GvL effect
after unrelated transplants, although the magnitude of this
effect in this setting is uncertain. Our observation is in line
with findings of a recent ALWP study of AML patients
transplanted in first relapse. The use of unrelated donors in
those very high-risk patients was associated with decreased
risk of subsequent relapse post-transplant, as compared to
matched sibling donors [22]. Recent publications of the
ALWP of the EBMT suggests the potential role of pro-
phylactic or pre-emptive donor lymphocyte infusions aimed
to increase the GvL effect and prevent relapse in high-risk
AML patients, which could be of interest also in 3q26 AML
patients [23]. Therapeutic use of DLI in relapsing patients in
our cohort unfortunately proved ineffective. In another
publication by the ALWP an enhanced GvL effect was
observed with the use of peripheral blood as compared to
bone marrow grafts in patients undergoing alloHSCT with
RIC [24]. However, stem-cell source did not show any
correlation with RI and LFS in the current analysis. As for
the type of the conditioning, preliminary results of a ran-
domized trial by the Blood and Marrow Clinical Trials
Network comparing MAC and RIC in patients with AML
indicated that myeloablative regimens are more effective,
leading to substantially decreased relapse incidence and
improved LFS and OS after alloHSCT [25]. However data
on the role of conditioning intensity in AML patients with
very high-risk cytogenetic categories such as monosomal
karyotype acute myeloid leukemia (MK-AML) are still
conflicting. In a recent ALWP–EBMT analysis, relapse rate
after alloHSCT in MK-AML was not significantly influ-
enced by the type of conditioning [26]. On the other hand,
in a study undertaken by the CIBMTR, MAC alloHSCT in
patients aged 41 to 60 years performed in MK-AML in first
complete remission led to a decreased risk of relapse [27].
In the present study, conditioning intensity did not show
impact on disease control in the whole group. Nevertheless
in patients transplanted in CR, 2-year OS probability for
those who received MAC vs. RIC was 41.5 vs. 19% (p=
0.036) in univariate analysis, which may support the use of
intensive conditioning. Only two factors were associated
with decreased risk of NRM in multivariate analysis,
namely CR at transplantation and presence of chromosome
7 monosomy. Remission status is a recognized factor for
reduced NRM and was first proposed by Gratwohl for
transplantation-risk assessment in patients with chronic
myeloid leukemia [28]. The interaction between additional
monosomy 7 and NRM in this study must be interpreted
very cautiously, since it may be due to small study
population and low number of NRM events, competitive
with high relapse incidence. Moreover, an additional dele-
terious effect of monosomy 7 in this entity was detected in a
previously published analysis of 103 newly diagnosed
patients with 3q26 AML or MDS [29]. In our study higher
RI seen in patients with monosomy 7 in the univariate
analysis was not confirmed in multivariate, as the present
study is probably underpowered to identify this effect.
Current study demonstrates that long-term disease con-
trol is possible with alloHSCT in a subgroup of patients.
Based on our findings no definite recommendations can be
made, but better results may be expected with transplanta-
tion in CR, in younger patients, and probably with the use
of MAC in patients transplanted in CR. High risk of pro-
gression after alloHSCT and the impact of disease status at
transplantation underline the urgent need to develop novel,
more effective pre- and post-transplant treatment strategies
for these patients.
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